{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-151834","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2023-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.960306+00:00","generated_at":"2026-06-14T17:29:18.543912+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sensei Biotherapeutics repurchases 4.45M shares from Apeiron at $1.58/sh, ends proxy contest","bullets":["Company to buy 4,454,248 shares from Apeiron Parties at $1.58/share, eliminating their entire beneficial ownership.","Apeiron withdraws its March 2023 notice to nominate three directors for the 2023 annual meeting.","Share repurchase does not change previously disclosed cash runway into second half of 2025.","Standstill and voting agreement applies through the earlier of 4 years or 30 days before 2027 annual meeting.","Company plans to initiate Phase 1/2 clinical trial of lead candidate SNS-101 in mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-151834","json":"https://secwatch.observer/filing/0001193125-23-151834.json","markdown":"https://secwatch.observer/filing/0001193125-23-151834.md","text":"https://secwatch.observer/filing/0001193125-23-151834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/0001193125-23-151834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/d488025d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T17:29:18.543912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"061ce55bf94491995697b1b97fbf43fdd32ca08b","claim":"Sensei Biotherapeutics, Inc. entered into Purchase Agreement with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the \"Apeiron Parties\") (effective 2023-05-23).","evidence_excerpt":"On May 23, 2023, Sensei Biotherapeutics, Inc. (the “Company”) entered into a Purchase Agreement (the “Purchase Agreement”) with Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the “Apeiron Parties”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312523151834/0001193125-23-151834-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd. (collectively, the \"Apeiron Parties\")"},{"label":"Effective","value":"2023-05-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}